Morice, Alyn H. http://orcid.org/0000-0002-6135-9610
Birring, Surinder S.
Smith, Jaclyn A.
McGarvey, Lorcan P.
Schelfhout, Jonathan
Martin Nguyen, Allison
Xu, Zhi Jin
Wu, Wen-Chi
Muccino, David R.
Sher, Mandel R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
https://doi.org/10.1007/s00408-021-00437-7
Patient preferences for the treatment of chronic cough: a discrete choice experiment
https://doi.org/10.1136/bmjresp-2023-001888
Funding for this research was provided by:
Merck
Article History
Received: 25 January 2021
Accepted: 6 March 2021
First Online: 7 April 2021
Declarations
:
: AHM has received consulting fees from Bayer, Bellus, Boehringer Ingelheim, Merck, Pfizer, Proctor & Gamble, and Shionogi; lecture fees from AstraZeneca and Boehringer Ingelheim; and grant support from Afferent, Infirst, Merck, and Proctor & Gamble. SSB has received grants from Merck & Co., Inc.; scientific advisory board and consultancy fees from Bayer, Menlo, Merck & Co., Inc., Patara, Pfizer, and Sanofi; speaker fees from Roche; and grants for travel and subsistence for attendance to scientific meetings from Boehringer Ingelheim. JAS has received grants and personal fees related to the submitted work from Afferent Pharmaceuticals/Merck & Co., Inc.; grants from Ario Pharma, Bayer, Bellus, GlaxoSmithKline, Menlo, and NeRRe Pharmaceuticals; personal fees from Ario Pharma, Bayer, Bellus, Boehringer Ingleheim, Chiesi, GlaxoSmithKline, Genentech, Menlo, Neomed, and NeRRe Pharmaceuticals; nonfinancial support from Vitalograph; and is a named inventor on a patent, owned by Manchester University NHS Foundation Trust and licensed to Vitalograph Ltd, describing the detection of cough from sound recordings. JAS is also funded by the NIHR Manchester Biomedical Research Centre and a Wellcome Investigator Award and is an NIHR Senior Investigator. LPM has received grants from Afferent Pharmaceuticals/Merck & Co., Inc., British Heart Foundation, Chiesi, EU Interreg VA Health & Life Science Programme, and NC3Rs; personal fees from Afferent Pharmaceuticals/Merck & Co., Inc., Applied Clinical Intelligence, and AstraZeneca; grants for travel and subsistence for attendance to scientific meetings from Boehringer Ingelheim, Chiesi, and GlaxoSmithKline; and advisory board/consultancy fees from Almirall, Boehringer Ingelheim, GlaxoSmithKline, and NAPP. JS, AMN, ZJX, W-CW, and DRM are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. MRS has received grants and personal fees from Afferent Pharmaceuticals/Merck & Co., Inc. and is a consultant for AstraZeneca, Bayer, Bellus, NeRRe Therapeutics, and Nocion.
: This study was performed in accordance with the ethical standards of the Declaration of Helsinki. Approval of the clinical study (NCT02612610) at each study site was granted by one of the following institutional review boards (IRBs)/independent ethics committees: the Health Research Authority NRES Committee (Jarrow, UK), Sterling IRB (Atlanta, GA), Western IRB (Puyallup, WA), University of Utah IRB (Salt Lake City, UT), Kaiser Permanente Southern California IRB (Pasadena, CA), St. Luke’s Hospital IRB (Chesterfield, MO), or Mayo Clinic IRB (Rochester, MN).
: All patients provided written informed consent before enrollment.